{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.5 (Appendix 5):', 'Updated to indicate CTCAE v5.0 or', 'To align with proper CTCAE', 'Management of Potential Infusion-', 'higher will be used to grade an infusion-', 'version planned for use.', 'Associated Adverse Events During', 'related response.', 'Study Drug Administration', 'Throughout', 'Minor editorial and document', 'As these changes are minor,', 'formatting revisions have been made', 'they have not been', 'throughout the document.', 'summarized.', 'Abbreviations: ADA = antidrug antibody; AE = adverse event; C-SSRS = Columbia Suicide Severity Rating Scale;', 'CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; eCRF = electronic case', 'report file; EQ-5D-5L = Euro Quality of Life; IRT = interactive response technology; IVIg = intravenous', 'immunoglobulin; MG = myasthenia gravis; MG-QoL15r = Revised Myasthenia Gravis Quality of Life 15-item', 'scale; PD = pharmacodynamic; PE = plasma exchange; PK = pharmacokinetic; PP = plasmapheresis; SAE = serious', 'adverse event; SUSAR = suspected unexpected serious adverse reaction', 'Page 106 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '11.', 'REFERENCES', 'Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials.', 'Muscle Nerve. 2012;45(6):909-917.', 'Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53-72.', 'Burns TM, Conaway M, Sanders DB. The MG Composite: A valid and reliable outcome', 'measure for myasthenia gravis. Neurology. 2010;74(18): 1434-1440.', 'Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-', 'QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle &', 'Nerve. 2016;54(6):1015-1022.', 'Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in', 'patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.', 'Cella D. Measuring Quality of Life in Neurological Disorders; Final Report of the Neuro-QOL', 'Study September 2010. 2010 2010. Report No.', 'Cetin H, Fulop G, Zach H, Auff E, Zimprich F. Epidemiology of myasthenia gravis in Austria:', 'rising prevalence in an ageing society. Wien Klin Wochenschr. 2012;124(21-22):763-768.', 'Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn:', 'distinct from the FcRn-IgG interaction. Biochemistry. 2006;45(15):4983-4990', 'Christensen PB, Jensen TS, Tsiropoulos I, et al. Mortality and survival in myasthenia gravis: a', 'Danish population based study. Journal of Neurology, Neurosurgery &amp; Psychiatry.', '1998;64(1):78-8', 'Dalakas MC. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA.', '2004;291:2367-2375.', 'Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients', 'with treatment refractory myasthenia gravis. Muscle & Nerve. 2018;58(1):99-105.', 'Fang F, Sveinsson O, Thormar G, et al. The autoimmune spectrum of myasthenia gravis: a', 'Swedish population-based study. Journal of internal medicine. 2015;277(5):594-604', 'Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant,', 'humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary', 'artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100(25):2499-2506', 'Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical', 'trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst.', '2011;16(2):84-91.', 'Page 107 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Ha JC, Richman DP. Myasthenia gravis and related disorders: Pathology and molecular', 'pathogenesis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.', '2015;1852(4):651-657.', 'Heldal AT, Owe JF, Gilhus NE, Romi F. Seropositive myasthenia gravis: a nationwide', 'epidemiologic study. Neurology. 2009;73(2):150-151.', \"Howard JF, Freimer M, O'Brien F, Wang JJ, Collins SR, Kissel JT. QMG and MG-ADL\", 'correlations: Study of eculizumab treatment of myasthenia gravis. Muscle & Nerve.', '2017;56(2):328-330.', 'Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared', 'to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research.', '2013;22(7):1717-1727.', 'Keshavjee S, Davis RD, Zamora MR, de PM, Patterson GA. A randomized, placebo-controlled', 'trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human', 'beings. J Thorac Cardiovasc Surg. 2005;129(2):423-428.', 'Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis', 'pathogenesis. Expert Rev Clin Immunol. 2008;4(1):43-52', 'Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to', 'thrombopoietin. Blood. 2001;98(12):3241-3248.', 'Little R, Yau L. Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs. Biometrics.', '1996;52(4): 1324-1333.', \"O'Kelley M RB. Clinical trials with missing data: a guide for practitioners. Statistics in Practice.\", 'Statistics in Practice. 1 ed. Chichester, West Sussex, UK: John Wiley & Sons, Ltd; 2014. p. 257-', '368.', 'Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.', 'Drugs Today (Barc ). 2005;41(3):165-170.', 'Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial', 'validity and internal consistency findings from three multisite studies with adolescents and', 'adults. Am J Psychiatry. 2011;168(12):1266-1277.', \"Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to\", 'statistical analysis using pattern mixture models. Pharmaceutical Statistics. 2013;12(6):337-347.', 'Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of', 'immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia', 'gravis. J Neuropathol Exp Neurol. 1978;37(2):212-223.', 'Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and', 'management of anaphylaxis: summary report--Second National Institute of Allergy and', 'Page 108 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}